

Drug resistance interpretation: PR

PI Major Mutations:

PI Accessory Mutations:

PR Other Mutations:

None

None

R5X • P9G • L10A • V11E • T12E • I13H • K14N • I15A • G17R • Q18P • L19Q • K20R • M36I • R41K • H69K • L89M

Protease Inhibitors

atazanavir/r (ATV/r)

Susceptible

darunavir/r (DRV/r)

Susceptible

fosamprenavir/r (FPV/r)

Susceptible

indinavir/r (IDV/r)

Susceptible

lopinavir/r (LPV/r)

Susceptible

nelfinavir (NFV)

Susceptible

saquinavir/r (SQV/r)

Susceptible

tipranavir/r (TPV/r)

Susceptible

PR comments

Other

- L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced in vitro susceptibility to LPV and DRV. L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations. L10R/Y are rare, non-polymorphic PI-selected mutations. Their effects on PI susceptibility have not been well studied. L10A is a highly unusual mutation at this position.
- K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for PI.	

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:

NNRTI Mutations:

RT Other Mutations:

M41L • E44D • L74I • V75M • M184V • L210W • T215F

K103N • V108I

V35I • N54I • A98S • V118I • K122E • D123S • I135M • K173A • T200A • Q207E • R211K • K219X • P236S • P243L • V245Q • P247Q • E248K • K249R • D250S • S251W • W252T • T253V • V254M • N255I • D256Y • I257R • Q258N • K259S • L260R • V261K • G262A • L264W

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	High-Level Resistance	doravirine (DOR)	Potential Low-Level Resistance
zidovudine (AZT)	High-Level Resistance	efavirenz (EFV)	High-Level Resistance
stavudine (D4T)	High-Level Resistance	etravirine (ETR)	Susceptible
didanosine (DDI)	High-Level Resistance	nevirapine (NVP)	High-Level Resistance
emtricitabine (FTC)	High-Level Resistance	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	High-Level Resistance		
tenofovir (TDF)	High-Level Resistance		

RT comments

NRTI

- M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.
- E44D is a relatively non-polymorphic accessory mutation; E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs.
- L74V causes intermediate ABC resistance. L74I causes low-level ABC resistance.
- V75T/M/A/S are nonpolymorphic accessory NRTI-selected mutations. They appear to have minimal phenotypic effects on AZT, ABC, and TDF.
- M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.
- L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and intermediate resistance to ABC and TDF.
- T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF.

NNRTI

- K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.
- V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations.

Other

- V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs.
- P236L is a rare mutation selected commonly by DLV, which appears to have little if any effect on current NNRTIs. P236S is a highly unusual mutation at this position.

Drug resistance mutation scores of NRTI: [Download CSV](#)

Rule	ABC ÷	AZT ÷	D4T ÷	DDI ÷	FTC ÷	3TC ÷	TDF ÷
<u>M41L</u>	5	15	15	10	0	0	5
<u>M41L + E44D + L210W + T215F</u>	5	5	5	5	0	0	5
<u>M41L + M184V + T215F</u>	10	0	0	0	0	0	0
<u>M41L + L210W</u>	10	10	10	10	0	0	10
<u>M41L + L210W + T215F</u>	10	0	0	0	15	15	10
<u>M41L + T215F</u>	10	10	10	10	5	5	10
<u>L74I</u>	15	0	0	60	0	0	5
<u>M184V</u>	15	-10	-10	10	60	60	-10
<u>L210W</u>	5	15	15	10	0	0	5
<u>L210W + T215F</u>	10	10	10	10	0	0	10
<u>T215F</u>	10	60	40	15	0	0	10
<u>V75M</u>	0	10	30	15	0	0	0
Total	105	125	125	155	80	80	60

Drug resistance mutation scores of NNRTI: [Download CSV](#)

Rule	DOR ÷	EFV ÷	ETR ÷	NVP ÷	RPV ÷
<u>V106I</u>	10	10	0	15	0
<u>K103N</u>	0	60	0	60	0
Total	10	70	0	75	0